Phase II Study of Axalimogene Filolisbac (ADXS-HPV) for Platinum-Refractory Cervical Carcinoma: an NRG Oncology/Gynecologic Oncology Group Study

OBJECTIVE: Women with persistent, recurrent, and/or metastatic cervical cancer have a poor prognosis. Even with the availability of cisplatin plus paclitaxel and bevacizumab, median overall survival (OS) is only 17.0 months, with median post-progression survival of approximately seven months. We stu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol
Hlavní autoři: Huh, Warner K., Brady, William E., Fracasso, Paula M., Dizon, Don S., Powell, Matthew A., Monk, Bradley J., Leath, Charles A., Landrum, Lisa M., Tanner, Edward J., Crane, Erin K., Ueda, Stefanie, McHale, Michael T., Aghajanian, Carol
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487015/
https://ncbi.nlm.nih.gov/pubmed/32641240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.06.493
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky